Drug news

Injectafer/Ferinject (Vifor/Luitpold) meets endpoints in two trials for Iron Replacement

Read time: 1 mins

Last updated:18th Nov 2011

Published:18th Nov 2011

Source: Pharmawand

Two large, multi-center, randomised, controlled clinical trials of Injectafer (US brand name of Ferinject, ferric carboxymaltose) from Vifor Pharma/Luitpold Pharma,were presented at the American Society of Nephrology�s (ASN) Kidney Week 2011.The first trial, poster FR-PO1394, compared Injectafer to oral iron or i.v.iron and the sevond trial, poster LB-PO3155, compared Injectafer to Venofer. Both trials met their efficacy and safety endpoints. The mean change in hemoglobin was statistically higher for Injectafer in both trials. The rates of the composite cardiovascular safety endpoint was statistically similar for Injectafer versus oral iron or i.v. standard of care.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Safety of switching from a Vitamin K antagonist to a non–Vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation.

FRAIL-AF trial investigators set out to study the question of whether frail, elderly patients with atrial fibrillation who were doing well with vitamin K antagonists (VKA) should be switched to direct-acting oral anticoagulants (DOAC).

1 mins

Drug news

FDA approves updated Lupkynis (voclosporin) label to include long term data from the Aurora Clinical Program.-- Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc. announced that the FDA has approved a label update for Lupkynis. The updated label no longer includes language indicating that the safety and efficacy of Lupkynis has not been established beyond one year.

3 min

Drug news

Phase III KEYNOTE-811 trial met dual primary endpoint of overall survival (OS) as first-line treatment in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.- Merck Inc.,

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

1 min

See all news